Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 13/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.49 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.49 |
| ▸ | ABAT | P80404 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.49 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.41 |
| ▸ | TLR2 | O60603 | 1/20 | 0.41 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.41 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | XDH | P47989 | 1/20 | 0.40 |
| ▸ | PTPRF | P10586 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29955135 | 1.00 | ERN1 (0.50) | ERN1ALDH1A1AOX1TRIM24HPGD | |
| SCHEMBL29952360 | 0.85 | ERN1 (0.50) | ERN1ALDH1A1AOX1TRIM24HPGD | |
| SCHEMBL1478225 | 0.84 | ERN1 (0.47) | ERN1ALDH1A1AOX1TDP1TUBB1 | |
| SCHEMBL911855 | 0.81 | ERN1 (0.44) | ERN1ALDH1A1AOX1HPGDTUBB1 | |
| SCHEMBL27149659 | 0.81 | ALDH1A1 (0.53) | ERN1ALDH1A1TDP1 | |
| SCHEMBL3936411 | 0.79 | ERN1 (0.51) | ERN1ALDH1A1AOX1TRIM24HPGD | |
| SCHEMBL27674605 | 0.79 | ERN1 (0.51) | ERN1ALDH1A1AOX1TRIM24HPGD | |
| SCHEMBL19792605 | 0.79 | ERN1 (0.43) | ERN1ALDH1A1AOX1TDP1TUBB1 | |
| SCHEMBL28057376 | 0.79 | ERN1 (0.43) | ERN1ALDH1A1AOX1HPGDTUBB1 | |
| SCHEMBL275497 | 0.78 | ERN1 (0.42) | ERN1ALDH1A1AOX1HPGDTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018182-A1 | GLUCOCORTICOID RECEPTOR AGONISTS | ELI LILLY AND COMPANY | 2024-01-18 | — | — | US | disclosed |
| US-20240018182-A1 | GLUCOCORTICOID RECEPTOR AGONISTS | ELI LILLY AND COMPANY | 2024-01-18 | — | — | US | disclosed |
| US-20240018182-A1 | GLUCOCORTICOID RECEPTOR AGONISTS | ELI LILLY AND COMPANY | 2024-01-18 | — | — | US | disclosed |
| CN-117043172-A | Glucocorticoid receptor agonists | 伊莱利利公司 | 2023-11-10 | — | — | CN | disclosed |
| US-11787834-B2 | Glucocorticoid receptor agonists | ELI LILLY AND COMPANY (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787834-B2 | Glucocorticoid receptor agonists | ELI LILLY AND COMPANY (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787834-B2 | Glucocorticoid receptor agonists | ELI LILLY AND COMPANY (US) | 2023-10-17 | — | — | US | disclosed |
| CN-116888137-A | Carboxy substituted glucocorticoid receptor agonists | 伊莱利利公司 | 2023-10-13 | — | — | CN | disclosed |
| US-20230227493-A1 | CARBOXY SUBSTITUTED GLUCOCORTICOID RECEPTOR AGONISTS | ELI LILLY AND COMPANY | 2023-07-20 | — | — | US | disclosed |
| US-20230227493-A1 | CARBOXY SUBSTITUTED GLUCOCORTICOID RECEPTOR AGONISTS | ELI LILLY AND COMPANY | 2023-07-20 | — | — | US | disclosed |
| US-20230227493-A1 | CARBOXY SUBSTITUTED GLUCOCORTICOID RECEPTOR AGONISTS | ELI LILLY AND COMPANY | 2023-07-20 | — | — | US | disclosed |
| US-20220306681-A1 | CARBOXY SUBSTITUTED GLUCOCORTICOID RECEPTOR AGONISTS | ELI LILLY AND COMPANY | 2022-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227493-A1 | CARBOXY SUBSTITUTED GLUCOCORTICOID RECEPTOR AGONISTS | NR3C1, MC2R, NR3C2 | ERN1 2526/4885ALDH1A1 2971/4885AOX1 1335/4885 |
| US-20220306681-A1 | CARBOXY SUBSTITUTED GLUCOCORTICOID RECEPTOR AGONISTS | NR3C1, MC2R, NR3C2 | ERN1 2526/4885ALDH1A1 2971/4885AOX1 1335/4885 |
| US-20240018182-A1 | GLUCOCORTICOID RECEPTOR AGONISTS | NR3C1, NR3C2, MC2R | ERN1 1650/4885ALDH1A1 3227/4885AOX1 770/4885 |
| US-11787834-B2 | Glucocorticoid receptor agonists | NR3C1, NR3C2, MC2R | ERN1 1650/4885ALDH1A1 3227/4885AOX1 770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.